|
|
Post by falconquest on Dec 26, 2016 22:02:44 GMT -5
Lol. Two whom should be deactivated right away. Ok I will play along. Microsoft + Novo is bidding on MNKD against Google + Sanofi. Yeah, didn't Novo dump their inhaled insulin program? I bet they knew Afrezza was better so they'll buy Mannkind and then employ the deep pockets of Microsoft to act as marketing partner.........that has to be it! |
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Dec 27, 2016 11:49:29 GMT -5
Lol. Two whom should be deactivated right away. Ok I will play along. Microsoft + Novo is bidding on MNKD against Google + Sanofi. Its deeper then that. The NSA is working with MI6 to figure out who on the St is causing the FTD and naked shorting driving a share price down of a company that spends 5x's as much as it makes Dejude is helping with the investigation with his theroies on bid and ask |
|
|
|
Post by mikesmilitaria on Dec 27, 2016 13:13:30 GMT -5
Lantus' patent protection has passed and Sanofi's intended replacement Toujeo is a monumental flop. Whether you go with the popular equation Afrezza + Tresiba + CGM or the equation Afrezza + generic insulin gargline + CGM, either equation = Sanofi being out of the equation. When the SEC ends the confidential treatment of sections of the License & Collaboration Agreement between MannKind and Sanofi-Aventis in June 2017, more than a few theories will be proven and/or disproven. Good fortune all.  Read more: mnkd.proboards.com/thread/6906/afrezza-lantus-victory-over-dextrose#ixzz4U3zgbI5q__________________________________________ It's a great coincidence that Hakan's departure from MNKD is June 2017. |
|
|
|
Post by kbrion77 on Dec 27, 2016 13:47:43 GMT -5
Lantus' patent protection has passed and Sanofi's intended replacement Toujeo is a monumental flop. Whether you go with the popular equation Afrezza + Tresiba + CGM or the equation Afrezza + generic insulin gargline + CGM, either equation = Sanofi being out of the equation. When the SEC ends the confidential treatment of sections of the License & Collaboration Agreement between MannKind and Sanofi-Aventis in June 2017, more than a few theories will be proven and/or disproven. Good fortune all. Read more: mnkd.proboards.com/thread/6906/afrezza-lantus-victory-over-dextrose#ixzz4U3zgbI5q__________________________________________ It's a great coincidence that Hakan's departure from MNKD is June 2017. Every single theory that you spewed on Yahoo Message Boards for years were disproved time and time again. I would have told everyone here to go back on there and check your lunacy posts but oh wait I forgot they deleted the entire board over there with no record. There is no more SNY, there is no grand conspiracy of a 3-way marriage between SNY/MNKD/Google. Mannkind is essentially a start up bio-pharmaceutical company attempting to sell their one and only product with their backs against the wall. I am hoping the moderators catch on about your ambition for the board here. |
|
|
|
Post by mnholdem on Dec 27, 2016 15:13:04 GMT -5
mikesmilitaria,
If you'd read this thread a little further past my post that you quoted (above), you'd have read where I corrected the expiration date to November 10, 2017 (and a link to the SEC-filing of the CT order was provided). So there is no coincidence between the CT order expiration and Hakan's departure...unless you're referring to the same year?
Sorry...
|
|
|
|
Post by agedhippie on Dec 27, 2016 18:32:47 GMT -5
Lantus' patent protection has passed and Sanofi's intended replacement Toujeo is a monumental flop. Whether you go with the popular equation Afrezza + Tresiba + CGM or the equation Afrezza + generic insulin gargline + CGM, either equation = Sanofi being out of the equation. A year after launch, Basaglar sales for the last quarter were only $19 million so Sanofi's non-US Lantus markets must be in good shape if that is all they lost. Sanofi will take a hit in the US next year but even that is contained since of the big three (80% of the US market) Express Scripts and OptumRx will still both carry Lantus as tier 2 although CVS will not. Toujeo sales? Q3 sales were close on $175 million which is not bad only a year and half after launch and ahead of where Lantus was. If that is a monumental flop I wish Afrezza had done the same but where are we? Sanofi know what they are doing. This is not their first drug to come off patent protection. |
|
|
|
Post by brotherm1 on Dec 27, 2016 18:45:55 GMT -5
I wonder how many sales reps SNY has selling Toujeo. Just curious. I believe someone on here recently found information from somewhere that SNY had around 300 reps selling Aftezza - if I recall correctly (or pehaps it was even less)? Just curious how many Toujeo reps and how much they gross per rep.
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Dec 27, 2016 18:47:52 GMT -5
A lot of corrections to the facts stated?
|
|
